Montelucaste Baldacci (Montelukast)

• Montelukast is a leukotriene receptor antagonist used to manage conditions driven by leukotriene‑mediated inflammation.
• Asthma: reduces bronchospasm frequency and improves overall disease control in patients with persistent asthma.
• Allergic rhinitis: relieves nasal congestion, sneezing, and itching associated with seasonal or perennial allergic rhinitis.
• Exercise‑induced bronchoconstriction: helps prevent airway narrowing during or after physical activity in susceptible individuals.

• Montelukast selectively antagonizes the cysteinyl leukotriene receptor type 1 (CysLT1) on airway smooth muscle, endothelial cells and inflammatory cells. By blocking binding of leukotriene D4 and related mediators, it prevents leukotriene‑induced bronchoconstriction, mucus secretion, vascular permeability, and eosinophilic inflammation, thereby improving airway patency and reducing allergic inflammation. The effect is dose‑independent and contributes to long‑term control of airway hyper‑responsiveness. This mechanism underlies its use in both chronic asthma management and allergic rhinitis therapy.

Montelukast may cause a range of adverse reactions, varying from mild to serious, and patients should be aware of potential side effects.

Common Side Effects

• Headache: mild to moderate head pain that may occur shortly after dosing.
• Abdominal pain: discomfort or cramping in the stomach area, often transient.
• Cough: dry or productive cough that can appear during treatment.
• Fatigue: feeling unusually tired or low in energy without exertion.

Serious or Rare Side Effects

• Neuropsychiatric events: agitation, mood changes, depression, or suicidal thoughts requiring immediate medical attention.
• Severe allergic reactions: rash, urticaria, swelling, or anaphylaxis that may be life‑threatening.
• Hepatic effects: elevated liver enzymes or hepatitis, indicated by jaundice or abnormal blood tests.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

• Pregnancy: safety not established; use only if potential benefit justifies potential risk.
• Breastfeeding: unknown excretion; weigh benefits against possible infant exposure.
• Pediatric use: dosage determined by age and weight; monitor growth and development.
• Concomitant asthma therapy: do not replace inhaled corticosteroids; continue controller medications.
• Neuropsychiatric monitoring: observe for mood changes, depression, or suicidal thoughts.
• Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Montelukast can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid)

• Phenobarbital: enzyme induction may reduce montelukast plasma concentrations.
• Rifampin: strong CYP3A4 inducer that can markedly lower drug exposure.
• St. John’s wort: herbal CYP3A4 inducer potentially decreasing therapeutic effect.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs, SNRIs): may increase risk of neuropsychiatric side effects.
• Warfarin: occasional reports of altered INR; monitor coagulation parameters.
• Beta‑agonists: additive bronchodilation effect; assess for excessive airway relaxation.